Click here to view the programme of Session 2a

Chairs:
Elizabeth Smyth, medical-oncologist, Cambridge University Hospital Cambridge, United Kingdom
Sun Young Rha, medical oncologist, Yonsei Cancer Center, Seoul, South Korea

15:30 HER2-targeted treatment
Tania Fleitas, medical-oncologist, University Hospital Valencia, Spain

15:50 Claudin 18.2-targeted treatment
Sam Klempner, medical-oncologist, Massachusetts General Hospital and Harvard Medical School, Boston, USA

16.10 FGFR2-targeted treatment approaches
Zev Wainberg, medical-oncologist, University of California, Los Angeles, USA

16:30 Accepted oral abstract 01.1.10: Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy (PECORINO trial)
Oleksii Dobrzhanskyi, Surgeon, National Cancer Institute, Ukraine

16.40 Accepted oral abstract 01.1.11: T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer
Zirui Xue, Resident, Zhongshan Hospital, Fudan University, China

16:50 Accepted oral abstract 01.1.12: New chemotherapy regimen in stage IV gastric cancer, data from MetaGastro
Silvia Ministrini, Surgeon, University if Brescia, Italy

17:00 End of session